Biodegradable Covalent MOR Antagonist Conjugates for Sustained Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current MOR antagonists, such as naloxone, are ineffective against highly potent synthetic opioids due to rapid metabolism and high potency, requiring large doses and frequent administration to reverse opioid toxicity, and fail to prevent renarcotization.
Innovation Solution
Development of polymer conjugates of MOR antagonists, covalently attached to biodegradable polymers, forming nanoparticles for sustained delivery, providing a steady dose to overcome synthetic opioid toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If naloxone is administered to reverse opioid toxicity, then the antagonistic effect is achieved, but the duration of action is too short due to rapid metabolism
Solution Approach 1:
The patent applies preliminary action by pre-attaching the MOR antagonist to a biodegradable polymer carrier before administration. This pre-prepared conjugate system ensures that the antagonist is released in a controlled manner over time, providing sustained therapeutic effect without requiring frequent re-administration. The polymer carrier is designed to degrade at a controlled rate, releasing the antagonist as needed to maintain effective concentrations throughout the treatment period.
Solution Approach 2:
The patent uses a biodegradable polymer as an intermediary carrier between the MOR antagonist and the biological system. This polymer mediator protects the antagonist from rapid metabolism and clearance, while its controlled degradation releases the active compound in a sustained manner. The polymer acts as a temporary reservoir that modulates the release kinetics, bridging the gap between initial administration and complete metabolic clearance.
2Reliability
If large doses of naloxone are administered to overcome high potency synthetic opioids, then the antagonistic effect is enhanced, but precipitated withdrawal is caused
Solution Approach 1:
The patent applies dynamics by transitioning from static bolus dosing to dynamic controlled-release dosing. The polymer conjugate system provides a time-varying release profile that maintains antagonist concentration within a therapeutic window. This dynamic release prevents both sub-therapeutic levels (ineffective reversal) and supra-therapeutic levels (precipitated withdrawal), adapting the delivery rate to match the degradation kinetics of the polymer and the metabolic clearance of the antagonist.
Solution Approach 2:
The patent changes the pharmacokinetic parameters of the MOR antagonist by conjugating it to a biodegradable polymer. This modification alters the release profile from rapid clearance to sustained release, changing the concentration-time profile from peak-and-trough patterns to a more constant, controlled delivery. The polymer conjugation effectively transforms the dosing regime from intermittent large doses to continuous low-dose administration, maintaining therapeutic efficacy while avoiding harmful side effects.
3Reliability
If frequent administration of naloxone is performed to prevent renarcotization, then sustained antagonism is achieved, but treatment complexity increases
Solution Approach 1:
The patent merges multiple dosing events into a single administration event. By incorporating the MOR antagonist into a biodegradable polymer matrix, the system combines what would otherwise require multiple separate injections into one unified delivery system. The polymer degradation kinetics are designed to match the therapeutic requirements, providing sustained release equivalent to multiple doses but administered as a single formulation, thereby simplifying the treatment protocol while maintaining sustained antagonism.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polymer conjugates offer a sustained, sufficient dose of MOR antagonists, effectively preventing opioid overdose and abuse, maintaining an extended MOR blockade without causing precipitated withdrawal.
Implementation Method 1
The polymer conjugate may be administered in the form of therapeutic nanoparticles. Methods of making the polymer conjugates of the MOR antagonists and methods of making the nanoparticles of the polymer conjugates are also provided.
Data Source
AI summary
Polymer conjugates comprising a hydrophobic biodegradable polymer covalently attached to a mu opioid receptor (MOR) antagonist are described. Biodegradable covalent nanoparticles comprising the hydrophobic biodegradable polymer covalently attached to a MOR antagonist are provided as a vehicle for the sustained delivery of the MOR antagonist. The described MOR antagonist delivery system may be used to more effectively prevent or overcome the toxic effects of synthetic opioids.